Merck Acquires Daxas Rights
April 27, 2010
Recently, Merck entered into a co-promotion agreement with Nycomed for the commercialization of Daxas in Canada and certain European countries, according to Zacks Equity Research. The drug is meant to treat patients with chronic obstructive pulmonary disease (COPD). The two companies have also signed a distribution agreement for Daxas in the UK. The drug has been developed with Forest Laboratories. Nycomed will receive undisclosed upfront fees and payments on the achievement of certain milestones. The marketing application for Daxas was submitted in Europe, Canada and the US in 2009. Last week, Nycomed received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending the approval of Daxas in the EU.